Detalhe da pesquisa
1.
Impact of 68GA-PSMA PET / CT on treatment of patients with recurrent / metastatic high risk prostate cancer - a multicenter study.
Int Braz J Urol
; 44(5): 892-899, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30088720
2.
A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415).
Eur J Cancer
; 158: 63-71, 2021 Oct 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-34655838
3.
Impact of 68GA-PSMA PET / CT on treatment of patients with recurrent / metastatic high risk prostate cancer - a multicenter study
Int. braz. j. urol
; 44(5): 892-899, Sept.-Oct. 2018. tab, graf
Artigo
em Inglês
| LILACS | ID: biblio-975631
4.
Phase II trial of neoadjuvant gemcitabine and cisplatin in patients with resectable bladder carcinoma.
Int Braz J Urol
; 33(5): 630-8; discussion 638, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-17980060
5.
Phase II trial of neoadjuvant gemcitabine and cisplatin in patients with resectable bladder carcinoma
Int. braz. j. urol
; 33(5): 630-638, Sept.-Oct. 2007. graf, tab
Artigo
em Inglês
| LILACS | ID: lil-470213
6.
Re: Phase II trial of neoadjuvant gemcitabine and cisplatin in patients with resectable bladder carcinoma
Int. braz. j. urol
; 33(6): 840-841, Nov.-Dec. 2007.
Artigo
em Inglês
| LILACS | ID: lil-476651